ANIK — Anika Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $204.56m
- $148.93m
- $119.91m
Annual cashflow statement for Anika Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24 | 4.13 | -14.9 | -82.7 | -56.4 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 40.1 | 3.65 | 21.9 | 85.1 | 66.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -12.9 | -11.9 | -11.8 | -12.1 | -13.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 13.1 | 8.4 | 4.41 | -1.79 | 5.4 |
| Capital Expenditures | -1.63 | -5.14 | -7.49 | -5.43 | -8.33 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -69.6 | 2.02 | 0 | 0 | — |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -71.3 | -3.12 | -7.49 | -5.43 | -8.33 |
| Financing Cash Flow Items | -4.74 | -7.71 | -4.58 | -1.35 | -1.89 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.77 | -6.78 | -4.85 | -6.32 | -12.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -61.6 | -1.43 | -8.06 | -13.5 | -15.7 |